B7 Therapeutics

B7 Therapeutics is a biotechnology company dedicated to discovering and developing next-generation cancer immunotherapies by targeting the B7 family of immune-regulating molecules. Founded by Dr. Lieping Chen, a pioneer in the discovery of the PD-1/PD-L1 pathway, the company leverages deep expertise in costimulatory and coinhibitory pathways to address "cold" tumors that do not respond to current checkpoint inhibitors. Their pipeline primarily focuses on novel targets such as B7-H3 and B7-H4, utilizing monoclonal antibodies and other advanced modalities to modulate the tumor microenvironment. The company aims to expand the reach of immunotherapy to a broader range of cancer patients through precision targeting of these immune checkpoints. By focusing on the "dark matter" of the immune system, B7 Therapeutics seeks to unlock new therapeutic possibilities in oncology.